Drug Database
Back to search

Poland· PL-100299622

Selincro

A nalmefene product containing nalmefenum, registered in Poland by H. Lundbeck A/S. The same ATC class is registered in 14 of our 19 countries.

ATC N07BB05

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedSelincroATCN07BB05REGISTER NO.PL-100299622PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about nalmefenumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Nalmefene is registered in 14 of 19 countries.

Countries holding a registration under ATC N07BB05 (nalmefene), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 9 of them publish a price we can compare per daily dose
Search nalmefene products by name

Nalmefene · ATC N07BB05

14 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of nalmefene costs, country by country.

Normalised to the WHO defined daily dose (18 mg), the median price runs from $3.31 in France to $6.33 in Switzerland — a ×1.9 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Nalmefene · price per daily dose (18 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$6.33
  • FR France$3.31
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Nalmefenum
Manufacturer
H. Lundbeck A/S
Country
Poland (PL)
ATC code
N07BB05
ATC class
Nalmefene
Defined daily dose
18 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05702157142033
  • gtin
    05702157142040

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

5 interactions on record for nalmefene.

Graded by severity as the source publishes them — 4 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check nalmefene against other medicinesHow interaction checks work

Nalmefene · interactions on record

5 records

  • 4 moderate
  • 1 minor

Most severe, free to view

  • Methylnaltrexone bromideA06AH01moderate
  • NaloxegolA06AH03moderate
  • NaldemedineA06AH05moderate
  • GlimepirideA10BB12moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Nalmefene in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All nalmefene products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • Germany · Nalfino
  • France · Nalmefene Biogaran
  • Iceland · Selincro
  • Norway · Selincro

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/a2d5a95e-d157-4c00-850d-170f7d72c1d7
GET /v1/drugs/a2d5a95e-d157-4c00-850d-170f7d72c1d7?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "18 mg",
  "packaging": "05702157142033 ¦ Rp ¦ EU/1/12/815/001 ¦ 84783\n7 tabl.\n05702157142040 ¦ Rp ¦ EU/1/12/815/002 ¦ 84784\n14 tabl.\nRp ¦ EU/1/12/815/003 ¦ 105540\n28 tabl.\nRp ¦ EU/1/12/815/003 ¦ 105541\n42 tabl.\nRp ¦ EU/1/12/815/005 ¦ 105542\n98 tabl.\nRp ¦ EU/1/12/815/006 ¦ 105543\n49 tabl.\nRp ¦ Skasowane ¦ EU/1/12/815/007 ¦ 122841\n14 tabl.\nRp ¦ Skasowane ¦ EU/1/12/815/008 ¦ 122842\n28 tabl.",
  "substance": "Nalmefeni hydrochloridum dihydricum 18 mg",
  "common_name": "Nalmefenum",
  "pl_product_id": "100299622",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about nalmefene.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console